{
    "clinical_study": {
        "@rank": "99307", 
        "arm_group": [
            {
                "arm_group_label": "Azzalure 10 Speywood units/injection", 
                "arm_group_type": "Experimental", 
                "description": "Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)"
            }, 
            {
                "arm_group_label": "Azzalure, 10 Speywood units/injection", 
                "arm_group_type": "Active Comparator", 
                "description": "Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized, evaluator-blinded, comparative, study to evaluate the efficacy and safety of\n      different injection volumes of botulinum toxin type A, Azzalure, in the glabellar lines."
        }, 
        "brief_title": "A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Glabellar Frown Lines", 
        "detailed_description": {
            "textblock": "Clarification regarding injection volumes for the different study groups:\n\n      Subjects will be randomized to Group A or Group B (1:1).\n\n        -  Group A: 0,63ml NaCl will be used to reconstitute toxin in the vial. 0,05mL will be\n           injected (equal to a dose of 10s.U.)\n\n        -  Group B: 1,25ml NaCl will be used to reconstitute toxin in the vial. 0,1 mL will be\n           injected (equal to a dose of 10s.U.).\n\n      The two different reconstitution volumes (each containing a dose of 10s.U. botulinum toxin\n      A) will be compared as described under objectives."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Women, 18 to 64 years of age\n\n          -  Subjects seeking treatment for moderate to severe glabellar lines when the severity\n             of these lines has an important psychological impact on the subject, as determined by\n             the investigator.\n\n        Key Exclusion Criteria:\n\n          -  Subjects previously treated with any botulinum toxin product.\n\n          -  Pregnant or breast feeding women or women intending to get pregnant in the next 12\n             months.\n\n          -  Subjects with signs and symptoms of eyelid or brow ptosis or signs of compensatory\n             frontalis muscle activity, as judged by the investigator.\n\n          -  Subjects with clinical or subclinical neuromuscular junctional disorders (e.g.\n             myasthenia gravis, Lambert Eaton syndrome or amyotrophic lateral sclerosis) or a\n             history of dysphagia or aspiration.\n\n          -  Subjects with previous or current diagnosis of Bell's paresis.\n\n          -  Subjects with known bleeding disorders or subjects who are taking thrombolytics or\n             anticoagulants.\n\n          -  Subjects who are taking anticholinergics or aminoglycoside antibiotics.\n\n          -  Any prior surgery in the facial area that, in the opinion of the investigator, may\n             interfere with the results.\n\n          -  Subjects treated with fillers, HA filler or permanent filler, in the upper face one\n             year or less from screening."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108158", 
            "org_study_id": "05PF1311", 
            "secondary_id": "2013-004646-42"
        }, 
        "intervention": {
            "arm_group_label": [
                "Azzalure 10 Speywood units/injection", 
                "Azzalure, 10 Speywood units/injection"
            ], 
            "description": ".", 
            "intervention_name": "Azzalure", 
            "intervention_type": "Drug", 
            "other_name": "botulinum toxin type A"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gothenburg", 
                        "country": "Sweden"
                    }, 
                    "name": "G\u00f6teborgs Plastikkirurgiska Center"
                }, 
                "investigator": {
                    "last_name": "Dan Fagrell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uppsala", 
                        "country": "Sweden"
                    }, 
                    "name": "Anna Neuromuskul\u00e4r Konsult"
                }, 
                "investigator": {
                    "last_name": "Anna Rostedt Punga, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Evaluator-blinded, Comparative Study to Evaluate the Efficacy and Safety of Different Injection Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines", 
        "other_outcome": [
            {
                "description": "To evaluate effect on glabellar line severity", 
                "measure": "Blinded evaluator assessment of  severity of glabellar lines at rest and at maximum frown using the Merz Aesthetic 5-point scale", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "To evaluate the Compound Muscle Action Potential using electroneurography", 
                "measure": "Compound Muscle Action Potential (CMAP) reduction as percent of baseline CMAP measurement", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "To evaluate long term safety throughout the study period", 
                "measure": "Adverse Event reporting", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "To evaluate effect on glabellar line severity", 
                "measure": "Blinded evaluator assessment of  severity of glabellar lines at rest and at maximum frown using the Merz Aesthetic 5-point scale", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "To evaluate effect on glabellar line severity", 
                "measure": "Blinded evaluator assessment of  severity of glabellar lines at rest and at maximum frown using the Merz Aesthetic 5-point scale", 
                "safety_issue": "No", 
                "time_frame": "Day 3"
            }, 
            {
                "description": "To evaluate effect on glabellar line severity", 
                "measure": "Blinded evaluator assessment of  severity of glabellar lines at rest and at maximum frown using the Merz Aesthetic 5-point scale", 
                "safety_issue": "No", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "To evaluate effect on glabellar line severity", 
                "measure": "Blinded evaluator assessment of  severity of glabellar lines at rest and at maximum frown using the Merz Aesthetic 5-point scale", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "To evaluate effect on glabellar line severity", 
                "measure": "Blinded evaluator assessment of  severity of glabellar lines at rest and at maximum frown using the Merz Aesthetic 5-point scale", 
                "safety_issue": "No", 
                "time_frame": "Month 3"
            }, 
            {
                "description": "To evaluate effect on glabellar line severity", 
                "measure": "Blinded evaluator assessment of  severity of glabellar lines at rest and at maximum frown using the Merz Aesthetic 5-point scale", 
                "safety_issue": "No", 
                "time_frame": "Month 4"
            }, 
            {
                "description": "To evaluate effect on glabellar line severity", 
                "measure": "Blinded evaluator assessment of  severity of glabellar lines at rest and at maximum frown using the Merz Aesthetic 5-point scale", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "description": "To evaluate the Compound Muscle Action Potential using electroneurography", 
                "measure": "Compound Muscle Action Potential (CMAP) reduction as percent of baseline CMAP measurement", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "To evaluate the Compound Muscle Action Potential using electroneurography", 
                "measure": "Compound Muscle Action Potential (CMAP) reduction as percent of baseline CMAP measurement", 
                "safety_issue": "No", 
                "time_frame": "Day 3"
            }, 
            {
                "description": "To evaluate the Compound Muscle Action Potential using electroneurography", 
                "measure": "Compound Muscle Action Potential (CMAP) reduction as percent of baseline CMAP measurement", 
                "safety_issue": "No", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "To evaluate the Compound Muscle Action Potential using electroneurography", 
                "measure": "Compound Muscle Action Potential (CMAP) reduction as percent of baseline CMAP measurement", 
                "safety_issue": "No", 
                "time_frame": "Month 1"
            }, 
            {
                "description": "To evaluate the Compound Muscle Action Potential using electroneurography", 
                "measure": "Compound Muscle Action Potential (CMAP) reduction as percent of baseline CMAP measurement", 
                "safety_issue": "No", 
                "time_frame": "Month 3"
            }, 
            {
                "description": "To evaluate the Compound Muscle Action Potential using electroneurography", 
                "measure": "Compound Muscle Action Potential (CMAP) reduction as percent of baseline CMAP measurement", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "description": "To evaluate long term safety throughout the study period", 
                "measure": "Adverse Event reporting", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "To evaluate long term safety throughout the study period", 
                "measure": "Adverse Event reporting", 
                "safety_issue": "Yes", 
                "time_frame": "Day 3"
            }, 
            {
                "description": "To evaluate long term safety throughout the study period", 
                "measure": "Adverse Event reporting", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "To evaluate long term safety throughout the study period", 
                "measure": "Adverse Event reporting", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "To evaluate long term safety throughout the study period", 
                "measure": "Adverse Event reporting", 
                "safety_issue": "Yes", 
                "time_frame": "Month 1"
            }, 
            {
                "description": "To evaluate long term safety throughout the study period", 
                "measure": "Adverse Event reporting", 
                "safety_issue": "Yes", 
                "time_frame": "Month 3"
            }, 
            {
                "description": "To evaluate long term safety throughout the study period", 
                "measure": "Adverse Event reporting", 
                "safety_issue": "Yes", 
                "time_frame": "Month 4"
            }, 
            {
                "description": "To evaluate long term safety throughout the study period", 
                "measure": "Adverse Event reporting", 
                "safety_issue": "Yes", 
                "time_frame": "Month 6"
            }
        ], 
        "overall_contact": {
            "email": "anna.rostedt.punga@neuro.uu.se", 
            "last_name": "Coordinating Investigator Anna Rostedt Punga, MD", 
            "phone": "+46 737 74 98 07"
        }, 
        "overall_official": {
            "affiliation": "ANNA Neuromuskul\u00e4r Konsult", 
            "last_name": "Anna Rostedt Punga, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate effect on glabellar line severity", 
            "measure": "Blinded evaluator assessment of severity of glabellar lines at rest and at maximum frown using the Merz Aesthetic 5-point scale. (However no primary outcome measure is defined in the study protocol)", 
            "safety_issue": "No", 
            "time_frame": "Month 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108158"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Q-Med AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Q-Med AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}